Disease Overview：Hodgkin lymphoma（HL）
Hodgkin lymphoma (HL) is a B-cell-derived hematologic malignancy characterized by the presence of clonal Reed-Sternberg cells within reactive lymphoid tissue. It typically presents with painless lymphadenopathy—most commonly in cervical or mediastinal regions—alongside systemic “B symptoms” such as fever, drenching night sweats, and unintentional weight loss. Histopathological subtyping (e.g., nodular sclerosis, mixed cellularity) and staging via PET-CT, bone marrow biopsy, and laboratory assessment guide risk stratification. First-line therapy for early-stage disease often involves abbreviated chemotherapy (e.g., ABVD or AVD) ± involved-site radiotherapy; advanced-stage HL is managed with dose-intense regimens like BEACOPP, followed by response-adapted consolidation. With modern protocols, 5-year overall survival exceeds 85% for early-stage and 75–80% for advanced disease, underscoring HL’s status as one of the most curable solid and hematologic cancers.
China offers distinct advantages for international patients seeking HL management. Leading academic hospitals—such as Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—maintain internationally accredited hematology-oncology departments staffed by physicians trained at institutions including MD Anderson and Memorial Sloan Kettering. These centers deploy state-of-the-art PET-CT, digital pathology platforms, and flow cytometry for precise diagnosis and minimal residual disease monitoring. Notably, China’s high-volume HL practice supports robust clinical experience: over 2,000 new HL cases are treated annually across Tier-1 centers, contributing to refined treatment algorithms and published outcomes comparable to Western benchmarks. Crucially, comprehensive care—including chemotherapy, immunotherapy (e.g., brentuximab vedotin), and autologous stem cell transplantation—is delivered at approximately 40–60% lower cost than in the US or UK, without compromising protocol fidelity or supportive care standards.
As a dedicated medical tourism agency, we facilitate seamless access to this high-quality care for international patients. Our services include verified hospital referrals, transparent itemized pricing, visa coordination, on-ground clinical liaison, multilingual interpretation, accommodation logistics, and post-treatment follow-up support—all designed to reduce administrative burden and enhance therapeutic confidence.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hodgkin Lymphoma (Hematology)
Non-Surgical / Conservative / Medication-Based Therapy
*Indicated for all stages; first-line standard is ABVD chemotherapy.*
- •ABVD Regimen (4–6 cycles): Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
- *Total (6 cycles)*: $7,680–$9,120
- •Baseline & Monitoring Labs/Exams: CBC, LDH, ESR, renal/hepatic panel, CT/PET-CT (staging), pulmonary function test (pre-bleomycin)
- *Per-cycle labs (CBC, chemistry, LDH)*: $185/cycle × 6 = $1,110 - *Interim PET-CT (after 2 cycles)*: $1,020 - *End-of-treatment PET-CT*: $1,020
Surgical / Procedural / Interventional Options
*Surgery is not curative but supports diagnosis/staging or manages complications.*
- •Diagnostic Excisional Lymph Node Biopsy (required for definitive diagnosis)
- *Procedure fee (open biopsy)*: $1,360–$1,640 - *Pre-op workup (ECG, chest X-ray, coagulation panel, anesthesia consult)*: $320
- •Bone Marrow Biopsy & Aspiration (for stage IV or B-symptom evaluation)
- •Central Venous Catheter Placement (for prolonged chemo access)
- *Tunneled port (e.g., Port-a-Cath)*: $1,850
Special / Complex Condition Management
- •Relapsed/Refractory Disease: Brentuximab vedotin + bendamustine (2nd line)
- *Total (4 cycles)*: $17,000–$19,120
- •High-Risk Early-Stage (e.g., bulky mediastinal mass): Escalated BEACOPP (8 cycles)
- *Total*: $15,840–$18,080
- •Autologous Stem Cell Transplant (ASCT) (for chemosensitive relapse)
Quick Selection Guide
- •Young, fit, early-stage (IA–IIA): ABVD × 4 cycles + PET-CT monitoring → ~$10,950
- •Elderly (>65) or comorbid (COPD, renal impairment): AVD (bleomycin omitted) × 6 cycles → ~$9,200 (avoids pulmonary toxicity)
- •Advanced (III–IV) or bulky disease: ABVD × 6 + interim PET → ~$12,000
- •Relapsed after frontline: Brentuximab + bendamustine × 4 → ~$18,200, then ASCT if eligible → + $35,000
- •Budget-constrained (<$8,000): ABVD × 4 + rigorous outpatient monitoring; avoid PET-CT if clinically stable → ~$7,800
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hodgkin lymphoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Hodgkin lymphoma treatment with China top medical destinations:
